Atlas Trials

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

Clinical trial NCT01450826 · COMPLETED

Trial details

NCT number
NCT01450826
Sponsor
Katy Peters
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
NauseaVomitingGlioma
Start date
2014-06-24
Primary completion
2017-04-13
Enrollment
136

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.